Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Terminated 1No longer available 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Cholangiocarcinoma 1

Interventions

Oxaliplatin 95Fluorouracil 84Capecitabine 75Gemcitabine 72Leucovorin 68Nivolumab 67Bevacizumab 63pembrolizumab 60Magnetic Resonance Spectroscopy 52Specimen Handling 50Irinotecan 50durvalumab 46Radiotherapy 42atezolizumab 40Cisplatin 39Paclitaxel 37Biopsy 37130-nm albumin-bound paclitaxel 34Cetuximab 30Carboplatin 27Albumin-Bound Paclitaxel 26Taxes 24Drug Therapy 20dehydroftorafur 19Radiation 19Ipilimumab 19tislelizumab 18Surgical Procedures, Operative 17Standard of Care 17Docetaxel 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × derazantinib × Gastrointestinal × Clear all
NCT05174650 2025-12-05

Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 2 Active not recruiting
27 enrolled
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡